Day: September 20, 2022

WASHINGTON, Sept. 20, 2022 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced continued investment in the firm’s Global Insurance Services practice with the appointments of Vince Bodnar as a Senior Managing Director, Kevin Waterman as a Senior Director and Marc Zimmerman as a Senior Advisor. Mr. Bodnar, with almost 40 years of insurance industry experience, will be based in Philadelphia and lead the practice’s Life Insurance and Long-Term Care offerings in North America. Throughout his career, he has been a highly visible actuarial consultant helping insurers, regulators and policymakers develop solutions for in-force blocks of long-term care insurance policies and new product innovation. He was named one of the “20 Most Creative People in Insurance” by ThinkAdvisor in 2016. “Vince is one of the leading long-term...

Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 or 60 mg; mean mHTT reduction across both cohorts was 22% (median reduction 30%) from baseline 85 days post-single dose Wild-type huntingtin (wtHTT) protein levels through day 85 appear consistent with allele-selectivity Expanding single dose cohorts to optimize dose level with data expected in 1H 2023 Continued clinical validation of PRISM platform and PN stereochemistry Wave to host investor conference call and webcast at 8:30 a.m. ET today CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced a positive...

Picture 1 At 4:30 pm (Eastern) on Wednesday, September 21, 2022, TAAT® will be hosting its FQ3 2022 earnings call led by CEO Michael Saxon and CFO Joel Dumaresq. A full recording of the call will be published shortly after its conclusion.This earnings call was originally scheduled to take place on Thursday, September 22, 2022 at 4:15 pm (Eastern). The earnings call to take place on Wednesday, September 21, 2022 at 4:30 pm (Eastern) replaces the originally scheduled event. LAS VEGAS and VANCOUVER, British Columbia, Sept. 20, 2022 (GLOBE NEWSWIRE) — TAAT® GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT®”) is pleased to announce that it will host an earnings call on Wednesday, September 21, 2022 at 4:30 pm (Eastern) led by its Chief Executive Officer Michael Saxon and its Chief Financial...

FIND, the global alliance for diagnostics, together with German KfW bank co-funds development of Unyvero A30 RQ platform for low and middle income countries (LMICs) Initial project focuses on feasibility study for the rapid detection of antimicrobial resistance (AMR) markers from blood culture Feasibility phase of R&D project set to conclude by the end of Q1-2023 and co-funded by FIND with euro 700,000ROCKVILLE, Md., Sept. 20, 2022 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced the signing of an R&D collaboration agreement with FIND, the global alliance for diagnostics, for the Unyvero A30 RQ platform for use in rapid pathogen ID and AMR testing...

– The first and only treatment in Europe to treat patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants with a median overall survival age of about four years. – European Commission (EC) decision is based on the efficacy and safety data collected to date compared to data from a natural history study. – NULIBRY was BridgeBio’s first FDA-approved therapeutic; Sentynl acquired global rights to NULIBRY in March 2022. PALO ALTO, Calif. and SOLANA BEACH, Calif. and AHMEDABAD, India, Sept. 20, 2022 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, and Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. MONTREAL, Sept. 20, 2022 (GLOBE NEWSWIRE) — Dominion Water Reserves Corp. (“DWR” or the “Corporation”) (CSE:DWR), is pleased to announce that it has completed the second and final tranche (the “Second Tranche”) of its previously announced non-brokered private placement of up to $3,350,000 (the “Private Placement”) in units of the Corporation (each, an “Unit”) at a price of $100 per Unit. Private Placement Together with the previously announced closing of the First Tranche on July 5, 2022, a total of 33,350 Units were sold and issued under the Private Placement, for aggregate gross proceeds of $3,335,000. Under the Second Tranche, the Corporation sold 30,000 Units to 9474-8431 Quebec Inc. (“9474”) and certain joint actors for aggregate gross...

CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced the promotion of Phillip Samayoa, Ph.D., to chief strategy officer. Dr. Samayoa has led strategy, corporate and portfolio development at Generation Bio since he joined the company in 2017, most recently serving as senior vice president. “Phillip has been instrumental in building a holistic strategy for platform development that will enable its application to multiple genetic medicine modalities,” said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. “In this new role Phillip will lead corporate strategy, business development and discovery research, enabling the integration of these key strategic activities.” “We...

CENTREVILLE, Va., Sept. 20, 2022 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) was selected by U.S. Army Combat Capabilities Development Command, Chemical Biological Center (DEVCOM CBC) for an award on its Scientific, Technical Engineering, and Program Support Services (STEPSS) indefinite delivery, indefinite quantity (IDIQ) contract. The 10-year IDIQ, a multiple award contract with a program ceiling value of $869 million, will support the U.S. Army by providing acquisition life-cycle chemical and biological defense research, development, test, and evaluation support. “We stand ready to support DEVCOM CBC as they deliver on their vision of providing innovative chemical and biological defense capabilities to advance national security and global combat operations,” said Jon Moretta, president of Parsons’ engineered systems business...

Vancouver, BC, Sept. 20, 2022 (GLOBE NEWSWIRE) — Bessor Minerals Inc. (NEX:BST.H) (“Bessor” or the “Corporation”) is pleased to announce that, further to its news releases dated September 6, 2022, it has completed its previously announced non-brokered private ‎placement offering on September 19, 2022, pursuant to which Bessor issued 5,000,000 common ‎shares in the capital of Bessor (“Common Shares”) at a price of $0.05 per Common Share, for ‎aggregate gross proceeds of $250,000 (the “Private Placement”). All securities issued in ‎connection with the Private Placement are subject to a hold period of four months and one day ‎from September 19, 2022. The net proceeds from the Private Placement will be used for: potential exploration of Bessor’s properties; potential future acquisitions; and general working capital. The...